Newsroom

COLUMBUS, Ohio--(BUSINESS WIRE)--Clarametyx announced that Veronica Hall, PhD, has been promoted to CDO and Head of R&D and Brendan Doran, PharmD, has been promoted to COO....

ALBANY, N.Y.--(BUSINESS WIRE)--Soluna Holdings, Inc. (“Soluna” or the “Company”) (NASDAQ: SLNH), a developer of green data centers that converts renewable energy into computing power, today announced that it has closed the acquisition of the 150 MW Briscoe Wind Farm in West Texas for a total purchase price of $53.0 million. The transaction was financed through cash on the balance sheet and debt. The acquisition is expected to be immediately accretive, with projected Year-One Adjusted EBITDA of...

CLEVELAND--(BUSINESS WIRE)--Lincoln Electric schedules its first quarter 2026 earnings call for Thursday, April 30, 2026 at 10:00am (ET)....

LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Company”), a leading human-centric AI and humanoid robot manufacturer, today announced that it has successfully closed the previously announced sale of the Tokens.com domain portfolio to Bed Bath & Beyond, Inc. for total consideration of US$2.245 million. The transaction represents the monetization of non-core digital assets and does not involve the transfer of any operating busin...

COLUMBUS, Ohio--(BUSINESS WIRE)--Armatus has published data in Molecular Therapy Nucleic Acids describing TVR110, a first-in-class vectorized microRNA for CMT1A....

MONTRÉAL--(BUSINESS WIRE)--Triple Hair Group Inc. (« Triple Hair » ou la « Société »), une société spécialisée dans le développement de traitements novateurs contre l'alopécie androgénique (calvitie), a annoncé aujourd’hui que le premier patient a été dosé dans le cadre de son essai clinique de phase III au Canada visant à évaluer TH07, le traitement topique sur ordonnance breveté de la Société contre la calvitie. L’essai clinique de phase III (NCT07435012) est conçu pour évaluer l’innocuité et...

MONTRÉAL--(BUSINESS WIRE)--Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for androgenic alopecia (pattern baldness), today announced that the first patient has been dosed in its Phase III clinical trial in Canada evaluating TH07, the Company’s patented prescription topical treatment for male pattern hair loss. The Phase III clinical trial (NCT07435012) is designed to evaluate the safety and efficacy of TH07 in men wit...

AUSTIN, Texas--(BUSINESS WIRE)--Hart InterCivic announced Texas certification of its Verity Vanguard™ voting system, the sixth state to approve the VVSG 2.0‑certified system....

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Rising Dividend Achievers UCITS ETF 01.04.2026 RDVY LN IE000K5F6EL4 850,002.00 USD 18,587,309.36 21.867  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - June 01.04.2026 QJUN.LN IE000HFBJ0U0 3,650,002.00 USD 78,508,217.65 21.509  ...